{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T13:13:34Z","timestamp":1720098814287},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T00:00:00Z","timestamp":1540166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T00:00:00Z","timestamp":1540166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Dr. Reddys Laboratories Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s12325-018-0814-x","type":"journal-article","created":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T03:15:44Z","timestamp":1540178144000},"page":"1884-1893","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-World, Non-Interventional, Observational Study to Evaluate Effectiveness and Tolerability of Acotiamide Hydrochloride Hydrate in Treatment of Functional Dyspepsia"],"prefix":"10.1007","volume":"35","clinical-trial-number":[{"clinical-trial-number":"ctri\/2017\/11\/010421","registry":"10.18810\/clinical-trial-registry-india"}],"author":[{"given":"Shravan Kumar","family":"Porika","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishna Chaitanya","family":"Veligandla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shashi Kanth","family":"Muni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivani","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suyog C.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akhilesh D.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,22]]},"reference":[{"key":"814_CR1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1046\/j.1365-2036.2003.01706.x","volume":"18","author":"HB Ei-Serag","year":"2003","unstructured":"Ei-Serag HB, Talley NJ. Health-related quality of life in functional dyspepsia. Aliment Pharmacol Ther. 2003;18:387\u201393.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"814_CR2","doi-asserted-by":"publisher","first-page":"325","DOI":"10.5056\/jnm17018","volume":"23","author":"H Suzuki","year":"2017","unstructured":"Suzuki H. The application of the Rome IV criteria to functional esophagogastroduodenal disorders in Asia. J Neurogastroenterol Motil. 2017;23(3):325\u201333.","journal-title":"J Neurogastroenterol Motil"},{"key":"814_CR3","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/MOG.0000000000000306","volume":"32","author":"NJ Talley","year":"2016","unstructured":"Talley NJ, Walker MM, Holtmann G. Functional dyspepsia. Curr Opin Gastroenterol. 2016;32:467\u201373.","journal-title":"Curr Opin Gastroenterol"},{"issue":"4","key":"814_CR4","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1053\/j.gastro.2004.05.030","volume":"127","author":"J Tack","year":"2004","unstructured":"Tack J, Bisschops R, et al. Pathophysiology and treatment of functional dyspepsia. Gastroenterology. 2004;127(4):1239\u201355.","journal-title":"Gastroenterology"},{"issue":"12","key":"814_CR5","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1136\/gut.2008.158162","volume":"57","author":"L Van Oudenhove","year":"2008","unstructured":"Van Oudenhove L, Vandenberghe J, et al. Determinants of symptoms in functional dyspepsia: gastric sensorimotor function, psychosocial factors or somatisation? Gut. 2008;57(12):1666\u201373.","journal-title":"Gut"},{"issue":"12","key":"814_CR6","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1136\/gut.2005.085365","volume":"55","author":"S Kindt","year":"2006","unstructured":"Kindt S, et al. Impaired gastric accommodation and its role in dyspepsia. Gut. 2006;55(12):1685\u201391.","journal-title":"Gut"},{"issue":"6","key":"814_CR7","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/MOG.0b013e32834b7ca8","volume":"27","author":"J Tack","year":"2011","unstructured":"Tack J, et al. Functional dyspepsia. Curr Opin Gastroenterol. 2011;27(6):549\u201357.","journal-title":"Curr Opin Gastroenterol"},{"issue":"5","key":"814_CR8","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1517\/13543784.2011.562890","volume":"20","author":"J Tack","year":"2011","unstructured":"Tack J, et al. Acotiamide (Z-338, YM443), a new drug for the treatment of functional dyspepsia. Expert Opin Investig Drugs. 2011;20(5):701\u201312.","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"814_CR9","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1365-2982.2012.01897.x","volume":"24","author":"H Kusunoki","year":"2012","unstructured":"Kusunoki H, Haruma K, et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil. 2012;24(6):540.","journal-title":"Neurogastroenterol Motil"},{"key":"814_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2036.2012.05128.x","volume":"36","author":"BE Lacy","year":"2012","unstructured":"Lacy BE, Talley NJ, et al. Current treatment options and management of functional dyspepsia. Aliment Pharmacol Ther. 2012;36:3\u201315.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"814_CR11","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1620\/tjem.234.237","volume":"234","author":"S Mayanagi","year":"2014","unstructured":"Mayanagi S, Kishino M, et al. Efficacy of acotiamide in combination with esomeprazole for functional dyspepsia refractory to proton-pump inhibitor monotherapy. Tohoku J Exp Med. 2014;234(3):237\u201340.","journal-title":"Tohoku J Exp Med"},{"issue":"Suppl 1","key":"814_CR12","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1016\/j.jval.2018.04.554","volume":"21","author":"SC Mehta","year":"2018","unstructured":"Mehta SC, Shravan Kumar P, et al. Real world, non-interventional, observational study to evaluate effectiveness and tolerability of acotiamide hydrochloride hydrate in indian patients with functional dyspepsia. Value Health. 2018;21(Suppl 1):S82.","journal-title":"Value Health"},{"key":"814_CR13","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/j.1365-2036.2010.04566.x","volume":"33","author":"D Ang","year":"2011","unstructured":"Ang D, Talley NJ, et al. Endpoints used in functional dyspepsia drug therapy trials. Aliment Pharmaco1 Ther. 2011;33:634\u201349.","journal-title":"Aliment Pharmaco1 Ther"},{"key":"814_CR14","first-page":"207e16","volume":"15","author":"NJ Talley","year":"2001","unstructured":"Talley NJ, Verlinden M, et al. Quality of life in functional dyspepsia: responsiveness of the Nepean Dyspepsia Index and development of a new-10 item short form. Aliment Pharmacol Ther. 2001;15:207e16.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"814_CR15","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.coph.2008.09.009","volume":"8","author":"J Tack","year":"2008","unstructured":"Tack J. Prokinetics and fundic relaxants in upper functional GI disorders. Curr Opin Pharmacol. 2008;8(6):690\u20136.","journal-title":"Curr Opin Pharmacol"},{"issue":"4","key":"814_CR16","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1159\/000332404","volume":"84","author":"K Matsueda","year":"2011","unstructured":"Matsueda K, Hongo M, et al. A long-term study of acotiamide in patients with functional dyspepsia: results from an open-label phase III trial in Japan on efficacy, safety and pattern of administration. Digestion. 2011;84(4):261\u20138.","journal-title":"Digestion"},{"issue":"6","key":"814_CR17","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1136\/gutjnl-2011-301454","volume":"61","author":"K Matsueda","year":"2012","unstructured":"Matsueda K, Hongo M, et al. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut. 2012;61(6):821\u20138. https:\/\/doi.org\/10.1136\/gutjnl-2011-301454.","journal-title":"Gut"},{"issue":"7","key":"814_CR18","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/nmo.12805","volume":"28","author":"H Yamawaki","year":"2016","unstructured":"Yamawaki H, Futagami S, et al. Improvement of meal-related symptoms and epigastric pain patients with functional dyspepsia treated with acotiamide was associated with acylated ghrelin levels in Japan. Neurogastroenterol Motil. 2016;28(7):1037\u201347.","journal-title":"Neurogastroenterol Motil"},{"key":"814_CR19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.2152\/jmi.63.230","volume":"63","author":"S Shinozaki","year":"2016","unstructured":"Shinozaki S, et al. The effect of acotiamide on epigastric syndrome and post prandial distress syndrome in patients with functional dyspepsia. J Med Investig. 2016;63:230\u20135.","journal-title":"J Med Investig"},{"key":"814_CR20","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s40265-013-0100-9","volume":"73","author":"ML Mary","year":"2013","unstructured":"Mary ML, Scott LJ. Acotiamide: first global approval. Drugs. 2013;73:1377\u201383.","journal-title":"Drugs"},{"issue":"3","key":"814_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.5056\/jnm.2011.17.3.235","volume":"17","author":"UC Ghoshal","year":"2011","unstructured":"Ghoshal UC, et al. Epidemiology of uninvestigated and functional dyspepsia in Asia: facts and fiction. J Neurogastroenterol Motil. 2011;17(3):235\u201344.","journal-title":"J Neurogastroenterol Motil"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-018-0814-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0814-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0814-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T16:22:20Z","timestamp":1628612540000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-018-0814-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,22]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["814"],"URL":"https:\/\/doi.org\/10.1007\/s12325-018-0814-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,22]]},"assertion":[{"value":"21 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}